- PR Newswire•17 days ago
ISELIN, N.J., Aug. 12, 2016 /PRNewswire/ -- Echo Therapeutics, Inc. (ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced its financial results for the quarter ended June 30, 2016. Echo's Quarterly Report on Form 10-Q, as filed with the SEC, may be accessed on the SEC's website, www.sec.gov.
- Zacks•2 months ago
Shares of Echo Therapeutics Inc. (ECTE) plunged 17.3% to close at $1.48 on Jul 11, after the company announced that it has received a delisting notice from the Nasdaq.
- PR Newswire•2 months ago
ISELIN, N.J., July 8, 2016 /PRNewswire/ -- Echo Therapeutics, Inc. (ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that the company has received notice on July 8, 2016 from the Nasdaq Stock Market (Nasdaq) that trading of the Company's common stock will be suspended on Nasdaq at the opening of business on Tuesday, July 12, 2016, and Nasdaq will file a Form 25 Notification of Delisting with the Securities and Exchange Commission. Effective July 12, 2016, Echo expects that its common stock will trade on the OTCQB® Venture Market, operated by OTC Markets Group Inc. under its current trading symbol "ECTE." Echo anticipates that beginning Tuesday, July 12, 2016, investors will be able to view real-time best bid and ask quotes for "ECTE" at www.otcmarkets.com and through most online broker websites.
Echo Therapeutics, Inc. (ECTE)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||0.89 - 0.92|
|52wk Range||0.61 - 2.84|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-0.66|
|Avg Vol (3m)||71,366|
|Dividend & Yield||N/A (N/A)|